A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Overview
Paper Summary
The study proposes replacing "NAFLD" with "MASLD" (metabolic dysfunction-associated steatotic liver disease), reflecting the central role of metabolic dysfunction. It also proposes diagnostic criteria based on the presence of at least one cardiometabolic risk factor and creates a separate category ("MetALD") for patients with MASLD and increased alcohol consumption.
Explain Like I'm Five
Scientists changed the name of "fatty liver disease" to better show it's mostly caused by how your body uses food, not just fat. They also made a special name for people who have it and drink alcohol.
Possible Conflicts of Interest
Many authors disclosed consulting relationships with or receiving grants from pharmaceutical companies involved in NAFLD research and treatment.
Identified Limitations
Rating Explanation
This study used a robust, multi-stage Delphi process with a diverse panel of experts and patient advocates to reach consensus on new nomenclature for fatty liver disease. The thorough methodology, global representation, and inclusion of patient perspectives are strengths. However, potential bias in the Delphi method and the declared COIs of some authors slightly lower the rating.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →